
Highlights from iwMyeloma 2025: trial updates and practical considerations
VJHemOnc Podcast
00:00
Advancements in Myeloma Treatment
This chapter explores the pivotal advancements in myeloma treatment, emphasizing the role of Minimal Residual Disease (MRD) as a key endpoint for drug approval. It highlights the integration of new therapies like bispecific antibodies and CAR T-cell therapy, along with the importance of collaboration between academic institutions and community oncologists. Personal patient stories illustrate the transformative potential of these treatments, showcasing the need for adaptive strategies in managing care and improving outcomes.
Transcript
Play full episode